Resource
A novel PCSK9 Epigenetic Editor Achieves Maximal Pharmacology with Best-in-class Potency in Non-human Primates
May 4, 2025
EAS 93rd Congress
Press Release
nChroma Bio to Present at the American Society of Gene & Cell Therapy (ASGCT) 2025 Annual Meeting
April 28, 2025
Resource
CRMA-1001 an epigenetic editor for the treatment of chronic hepatitis B
March 21, 2025
Global Hepatitis Summit 2025
Resource
A potent epigenetic editor targeting human PCSK9 for durable reduction of low-density lipoprotein cholesterol levels
February 10, 2025
Nature Medicine
Media
nChroma Bio Raises $75M to Advance Epigenetic Editing for Hepatitis B and D Cure
December 13, 2024
ContagionLive
Media
Chroma, Nvelop merge to marry genetic medicine ‘cargo’ to delivery
December 11, 2024
Biopharma Dive
Press Release
Chroma Medicine and Nvelop Therapeutics Unite to Form nChroma Bio, Securing $75 Million to Accelerate Genetic Medicines
December 11, 2024
Media
Chroma, Nvelop startups merge to form nChroma Bio
December 11, 2024
Cell & Gene Therapy Review
Media
Chroma Medicine, Nvelop Therapeutics Merge as nChroma Bio with Focus on Epigenetic Therapies
December 11, 2024
Genetic Engineering & Biotechnology News (GEN)
Resource
Brainwide silencing of prion protein by AAV-mediated delivery of an engineered compact epigenetic editor
June 8, 2024
Epigenetic Medicine